Commercialization of medical artificial intelligence technologies: challenges and opportunities.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40676253.
- Also identified by DOI 10.1038/s41746-025-01867-w and PMC identifier 12271346.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Artificial intelligence (AI) is already having a significant impact on healthcare. For example, AI-guided imaging can improve the diagnosis/treatment of vascular diseases, which affect over 200 million people globally. Recently, Chiu and colleagues (2024) developed an AI algorithm that supports nurses with no ultrasound training in diagnosing abdominal aortic aneurysms (AAA) with similar accuracy as ultrasound-trained physicians. This technology can therefore improve AAA screening; however, achieving clinical impact with new AI technologies requires careful consideration of commercialization strategies, including funding, compliance with safety and regulatory frameworks, health technology assessment, regulatory approval, reimbursement, and clinical guideline integration.